4142:TPE
Adimmune Corp
15,85 NT$
arrow_downward
-1,86%(-0,30) 1D
19 nën, 1:30:08 m.d., GMT+8 · TWD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për 4142...
Hap
16,20 NT$
I lartë
16,25 NT$
I ulët
15,70 NT$
Kapitalizimi i tregut
6,81 mld
Vëllimi mesatar
1,09 mln
Vëllimi
1,60 mln
Raporti çmim/fitim
91,85
Maksimumi 52-javor
21,50 NT$
Minimumi 52-javor
15,65 NT$
Fitimet për aksion
0,17 NT$
Aksionet në qarkullim
235,29 mln
Numri i punonjësve
564
Hap
16,20 NT$
I lartë
16,25 NT$
I ulët
15,70 NT$
Kapitalizimi i tregut
6,81 mld
Vëllimi mesatar
1,09 mln
Vëllimi
1,60 mln
Raporti çmim/fitim
91,85
Maksimumi 52-javor
21,50 NT$
Minimumi 52-javor
15,65 NT$
Fitimet për aksion
0,17 NT$
Aksionet në qarkullim
235,29 mln
Numri i punonjësve
564
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
The Motley Fool
·
36 minuta më parë
The Semiconductor ETF Is on Track to Beat the S&P 500 for a 4th Straight Year. It Has Never Done That Before.
Yahoo Finance
·
58 minuta më parë
S&P 500, Nasdaq, Dow End Lower As Anthropic Trading Debut Fails To Provide Adequate Confidence — ANT, META, AAPL, GME In Focus
Traders Union
·
1 orë më parë
S&P 500 sees $2 trillion swing and 8.5 percent drop, Peter Tuchman notes
ChartMill
·
1 orë më parë
S&P 500 After-Hours Movers: Nov. 19, 2026
Profili
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Rreth Adimmune Corp
Drejtori ekzekutiv-
Punonjësit564
Themeluar më1965
Selia-
SektoriHealth Care
Industria-
Uebsajtiadimmune.com.tw